CHICAGO TRUST Co NA Buys 113 Shares of McKesson Co. (NYSE:MCK)

Share on StockTwits

CHICAGO TRUST Co NA boosted its stake in shares of McKesson Co. (NYSE:MCK) by 0.8% in the third quarter, Holdings Channel reports. The firm owned 14,377 shares of the company’s stock after acquiring an additional 113 shares during the period. CHICAGO TRUST Co NA’s holdings in McKesson were worth $1,965,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors also recently made changes to their positions in the company. Nuveen Asset Management LLC lifted its holdings in shares of McKesson by 573.3% during the second quarter. Nuveen Asset Management LLC now owns 1,811,727 shares of the company’s stock worth $243,478,000 after buying an additional 1,542,644 shares during the last quarter. FMR LLC lifted its holdings in shares of McKesson by 16.7% during the first quarter. FMR LLC now owns 5,094,147 shares of the company’s stock worth $596,321,000 after buying an additional 727,954 shares during the last quarter. Royal Bank of Canada lifted its holdings in shares of McKesson by 111.4% during the second quarter. Royal Bank of Canada now owns 733,978 shares of the company’s stock worth $98,640,000 after buying an additional 386,734 shares during the last quarter. BlackRock Inc. lifted its holdings in shares of McKesson by 2.1% during the second quarter. BlackRock Inc. now owns 15,097,053 shares of the company’s stock worth $2,028,894,000 after buying an additional 308,554 shares during the last quarter. Finally, Jacobs Levy Equity Management Inc. lifted its holdings in shares of McKesson by 9,927.2% during the first quarter. Jacobs Levy Equity Management Inc. now owns 202,550 shares of the company’s stock worth $23,711,000 after buying an additional 200,530 shares during the last quarter. 86.62% of the stock is owned by hedge funds and other institutional investors.

In related news, SVP Sundeep G. Reddy sold 422 shares of the company’s stock in a transaction on Monday, September 9th. The stock was sold at an average price of $143.79, for a total value of $60,679.38. Following the completion of the transaction, the senior vice president now directly owns 1,268 shares in the company, valued at $182,325.72. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Brian S. Tyler sold 6,000 shares of the company’s stock in a transaction on Monday, September 30th. The shares were sold at an average price of $135.00, for a total value of $810,000.00. Following the completion of the transaction, the chief executive officer now owns 18,192 shares of the company’s stock, valued at $2,455,920. The disclosure for this sale can be found here. Insiders sold 10,218 shares of company stock valued at $1,421,738 over the last 90 days. 0.88% of the stock is currently owned by corporate insiders.

MCK has been the subject of a number of research analyst reports. Morgan Stanley upped their price target on McKesson from $130.00 to $135.00 and gave the stock an “equal weight” rating in a report on Tuesday, August 27th. JPMorgan Chase & Co. initiated coverage on McKesson in a report on Monday, July 22nd. They set an “overweight” rating and a $164.00 price target for the company. Cleveland Research reiterated a “hold” rating on shares of McKesson in a report on Thursday, September 5th. Guggenheim initiated coverage on McKesson in a report on Monday, July 22nd. They set a “neutral” rating and a $152.00 price target for the company. Finally, Wolfe Research lowered McKesson from an “outperform” rating to a “peer perform” rating in a report on Monday, August 5th. Two equities research analysts have rated the stock with a sell rating, eight have issued a hold rating and two have assigned a buy rating to the company. McKesson presently has a consensus rating of “Hold” and an average price target of $147.20.

Shares of NYSE MCK traded up $1.96 during trading hours on Wednesday, reaching $132.23. The stock had a trading volume of 1,001,999 shares, compared to its average volume of 1,523,844. The business’s fifty day moving average is $140.34 and its two-hundred day moving average is $132.44. The company has a debt-to-equity ratio of 1.14, a current ratio of 1.01 and a quick ratio of 0.58. The company has a market cap of $24.08 billion, a price-to-earnings ratio of 9.74, a PEG ratio of 1.32 and a beta of 1.14. McKesson Co. has a twelve month low of $106.11 and a twelve month high of $150.82.

McKesson (NYSE:MCK) last issued its earnings results on Wednesday, July 31st. The company reported $3.31 EPS for the quarter, beating analysts’ consensus estimates of $3.04 by $0.27. The business had revenue of $55.73 billion during the quarter, compared to analyst estimates of $54.03 billion. McKesson had a return on equity of 30.73% and a net margin of 0.27%. McKesson’s revenue was up 5.9% on a year-over-year basis. During the same period in the prior year, the company posted $2.90 earnings per share. Sell-side analysts forecast that McKesson Co. will post 14.39 earnings per share for the current fiscal year.

The company also recently announced a quarterly dividend, which was paid on Tuesday, October 1st. Investors of record on Tuesday, September 3rd were paid a $0.41 dividend. This represents a $1.64 dividend on an annualized basis and a dividend yield of 1.24%. This is a positive change from McKesson’s previous quarterly dividend of $0.39. The ex-dividend date of this dividend was Friday, August 30th. McKesson’s dividend payout ratio is presently 12.09%.

McKesson Profile

McKesson Corporation provides pharmaceuticals and medical supplies in the United States and internationally. It operates in three segments: U.S. Pharmaceutical and Specialty Solutions, European Pharmaceutical Solutions, and Medical-Surgical Solutions. The company distributes branded, generic, specialty, biosimilar, and over-the-counter pharmaceutical drugs, as well as other healthcare-related products; and offers practice management, technology, clinical support, and business solutions to community-based oncology and other specialty practices.

Recommended Story: Percentage Decliners

Want to see what other hedge funds are holding MCK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for McKesson Co. (NYSE:MCK).

Institutional Ownership by Quarter for McKesson (NYSE:MCK)

Receive News & Ratings for McKesson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for McKesson and related companies with MarketBeat.com's FREE daily email newsletter.